ACET
Price
$2.99Alerts
Change
-$0.01 (-0.33%)
Updated
Nov 11 closing price
Capitalization
28.55M
125 days until earnings call
Intraday BUY SELL Signals
LNTH
Price
$101.56Alerts
Change
-$0.04 (-0.04%)
Updated
Nov 12, 12:02 PM (EDT)
Capitalization
6.57B
105 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACET vs LNTH

ACET vs LNTH Comparison Chart in %
View a ticker or compare two or three
VS
ACET vs. LNTH commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a Hold and LNTH is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ACET with price predictions
Nov 11, 2026

ACET sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for ACET moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for ACET entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Moving Average Convergence Divergence (MACD) for ACET just turned positive on November 04, 2026. Looking at past instances where ACET's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.238) is normal, around the industry mean (3.498). P/E Ratio (-0.293) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ACET’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for LNTH with price predictions
Nov 11, 2026

Aroon Indicator for LNTH shows an upward move is likely

LNTH's Aroon Indicator triggered a bullish signal on November 05, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 291 similar instances where the Aroon Indicator showed a similar pattern. In 250 of the 291 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on LNTH as a result. In 57 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.

LNTH moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for LNTH crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.

Following a +1.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where LNTH advanced for three days, in 258 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LNTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

LNTH broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. LNTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 41 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.008) is normal, around the industry mean (6.379). P/E Ratio (23.785) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.275) is also within normal values, averaging (183.387).

FUNDAMENTALS RATINGS
ACET vs LNTH: Fundamental Ratings
ACET
LNTH
OUTLOOK RATING
1..100
5110
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
59
Fair valued
PROFIT vs RISK RATING
1..100
10041
SMR RATING
1..100
9844
PRICE GROWTH RATING
1..100
9441
P/E GROWTH RATING
1..100
834
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACET's Valuation (47) in the Medical Distributors industry is in the same range as LNTH (59) in the Medical Specialties industry. This means that ACET’s stock grew similarly to LNTH’s over the last 12 months.

LNTH's Profit vs Risk Rating (41) in the Medical Specialties industry is somewhat better than the same rating for ACET (100) in the Medical Distributors industry. This means that LNTH’s stock grew somewhat faster than ACET’s over the last 12 months.

LNTH's SMR Rating (44) in the Medical Specialties industry is somewhat better than the same rating for ACET (98) in the Medical Distributors industry. This means that LNTH’s stock grew somewhat faster than ACET’s over the last 12 months.

LNTH's Price Growth Rating (41) in the Medical Specialties industry is somewhat better than the same rating for ACET (94) in the Medical Distributors industry. This means that LNTH’s stock grew somewhat faster than ACET’s over the last 12 months.

ACET's P/E Growth Rating (8) in the Medical Distributors industry is in the same range as LNTH (34) in the Medical Specialties industry. This means that ACET’s stock grew similarly to LNTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACETLNTH
RSI
ODDS (%)
Bullish Trend 7 days ago
85%
Bearish Trend 1 day ago
76%
Stochastic
ODDS (%)
N/A
Bearish Trend 1 day ago
74%
Momentum
ODDS (%)
N/A
Bullish Trend 1 day ago
72%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
88%
Bearish Trend 7 days ago
65%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
64%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ACET: $2.99 vs. LNTH: $101.60)
Brand notoriety: ACET and LNTH are both not notable
ACET represents the Biotechnology, while LNTH is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACET: 184% vs. LNTH: 79%
Market capitalization -- ACET: $28.55M vs. LNTH: $6.57B
ACET [@Biotechnology] is valued at $28.55M. LNTH’s [@Pharmaceuticals: Generic] market capitalization is $6.57B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Biotechnology] industry is $2.23B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACET’s FA Score shows that 1 FA rating(s) are green while LNTH’s FA Score has 0 green FA rating(s).

  • ACET’s FA Score: 1 green, 4 red.
  • LNTH’s FA Score: 0 green, 5 red.
According to our system of comparison, LNTH is a better buy in the long-term than ACET.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACET’s TA Score shows that 2 TA indicator(s) are bullish while LNTH’s TA Score has 5 bullish TA indicator(s).

  • ACET’s TA Score: 2 bullish, 3 bearish.
  • LNTH’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, LNTH is a better buy in the short-term than ACET.

Price Growth

ACET (@Biotechnology) experienced а -3.55% price change this week, while LNTH (@Pharmaceuticals: Generic) price change was +0.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.23%. For the same industry, the average monthly price growth was -4.22%, and the average quarterly price growth was +10.49%.

Reported Earning Dates

ACET is expected to report earnings on Mar 17, 2027.

LNTH is expected to report earnings on Feb 25, 2027.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (+4.23% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

ACET and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACET has been loosely correlated with VIR. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ACET jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACET
1D Price
Change %
ACET100%
-0.33%
VIR - ACET
42%
Loosely correlated
-0.15%
OGI - ACET
41%
Loosely correlated
+0.15%
RXRX - ACET
41%
Loosely correlated
+1.13%
IMTX - ACET
38%
Loosely correlated
+4.21%
COYA - ACET
38%
Loosely correlated
+1.58%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IXN131.284.40
+3.47%
iShares Global Tech ETF (IXN)
ACTS25.390.82
+3.34%
FIS Tactical Equity ETF (ACTS)
TDVI30.910.62
+2.05%
FT Vest Technology Dividend Target Income ETF (TDVI)
RAFE51.610.36
+0.71%
PIMCO RAFI ESG U.S. ETF (RAFE)
QBQV25.67N/A
N/A
AllianzIM Growth-100 Buffer5 ETF (QBQV)